Skip to main content
Premium Trial:

Request an Annual Quote

Ruedi Aebersold, Richard DiMarchi, Scott Tarrant, Denice Dee Denton, Martin Chemers, Alan Garber, Franziska Grieder, John Strandberg, William Haseltine, Thomas Shenk

Ruedi Aebersold was named to the scientific advisory board of Insilicos of Seattle. Aebersold is a co-founder of the Institute of Systems Biology and is now professor of systems biology for the Institute of Biotechnology at the Swiss Federal Institute of Technology in Zurich.


Richard DiMarchi was named to the board of directors of Isis Pharmaceuticals last week. DiMarchi is a professor of biomolecular sciences at Indiana University, Bloomington; a partner at Twilight Venture Fund in Indianapolis, and chairman of Ambrx of San Diego. Previously, he was the director of the biotechnology group at Eli Lilly Research Laboratories and the Biotechnology Industry Organization.


Scott Tarrant was named vice president of North American business development for Xceleron, a York, UK-based contract research organization. He will be responsible for establishing and building Xceleron’s presence in North America through the commercialization of the company’s accelerator mass spectrometry technology. The company plans to open offices in Maryland immediately and will add laboratory capabilities over the next twelve months. Tarrant previously managed genomics and preclinical CRO services at Gene Logic, coming there from TherImmune Research.


Denice Dee Denton, dean of the college of engineering at the University of Washington, last week was named chancellor of the University of California, Santa Cruz. She replaces MRC Greenwood, who was appointed UC provost and senior vice president of academic affairs in February. Martin Chemers, provost and executive vice chancellor of the Santa Cruz campus, will serve as acting UCSC chancellor until Denton takes office. Denton holds four degrees in electrical engineering from the Massachusetts Institute of Technology, including a PhD.


Alan Garber, a professor of medicine at Stanford University, last week was named to the board of directors of Exelixis. He is the founding director of both the university’s Center for Health Policy and the Center for Primary Care and Outcomes Research at the School of Medicine. He is also a staff physician at the Veterans Affairs Palo Alto Health Care system, associate director of the VA Center for Health Care Evaluation, and research associate and director of the Health Care Program of the National Bureau of Economic Research.


The National Center for Research Resources of the National Institutes of Health last week named Franziska Grieder as associate director of comparative medicine, replacing John Strandberg, who retired last December.


William Haseltine, the founder of Human Genome Sciences, joined the board of directors of San Francisco-based OneWorld Health, the non-profit pharmaceutical organization said last week.


Thomas Shenk was named to the board of directors of CV Therapeutics of Palo Alto, Calif., the firm said last week. Shenk is a professor in the department of molecular biology at Princeton University, and serves on the boards of directors of Merck and of Cell Genesys.

 

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.